Introduction And Objectives: Identifying hepatitis B virus (HBV) patients eligible for safe nucleos(t)ide analogues (NAs) discontinuation remains challenging. Discrepant data on combined HBV DNA and quantitative HBV surface antigen (qHBsAg) assessments are available. This study aimed to identify potential predictors for safe treatment discontinuation by evaluating clinical/virological outcomes in patients on long-term NA therapy.
Patients And Methods: A retrospective cohort of 139 chronic hepatitis B (CHB) patients - who consecutively started Entecavir or Tenofovir from 2007 to 2011 - was evaluated. The study population was selected based on anti-HBe positivity, absence of prior antiviral treatment, absence of non-HBV-related liver diseases or hepatocellular carcinoma (HCC), and long-term clinical/ultrasonographic/laboratory evaluations post-NA initiation. Serum samples collected before starting NA (T0) and over ten years (T1-T10) were tested for HBV DNA and qHBsAg.
Results: Twenty-two/139 (15.8 %) CHB patients (12 chronic hepatitis, 10 cirrhosis) met the inclusion criteria. All patients showed a significant decrease in liver stiffness values in the ten years of follow-up (p = 0.001), and no hepatic decompensation occurred. Three/22 (13.6 %) patients developed HCC. Ten/22 patients (45.5 %; group-A) had fluctuating HBV DNA, while other 10/22 (45.5 %; group-B) showed undetectable HBV DNA for 5-9 years with more significant qHBsAg decline (p = 0.04) than group-A. Two/22 (9.1 %) patients showed a critical qHBsAg decline up to seroconversion together with undetectable HBV DNA.
Conclusions: Persistent undetectable HBV DNA levels correlate with qHBsAg reduction and the potential HBsAg seroclearance, suggesting that long-term HBV DNA monitoring in NA-treated CHB patients might help identify candidates for treatment discontinuation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinre.2025.102566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing Hepatitis B virus infection, risk factors and immunization among particularly vulnerable tribal groups in Eastern India.
Sci Rep
March 2025
Department of Microbiology & One Health, ICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, India.
In a population-based survey, Hepatitis B virus (HBV) infection status, associated risk factors and vaccine coverage among the 4006 Particularly Vulnerable Tribal Groups (PVTG) participants of Odisha Tribal Family Health Survey (OTFHS) were assessed using various viral markers. All the HBsAg-positive sera were screened for viral load estimation, envelopment antigen (HBeAg) identification and liver profile parameters. The overall prevalence of HBsAg was 5.
View Article and Find Full Text PDFAmplification-free, OR-gated CRISPR-Cascade reaction for pathogen detection in blood samples.
Proc Natl Acad Sci U S A
March 2025
Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
Rapid and accurate detection of DNA from disease-causing pathogens is essential for controlling the spread of infections and administering timely treatments. While traditional molecular diagnostics techniques like PCR are highly sensitive, they include nucleic acid amplification and many need to be performed in centralized laboratories, limiting their utility in point-of-care settings. Recent advances in CRISPR-based diagnostics (CRISPR-Dx) have demonstrated the potential for highly specific molecular detection, but the sensitivity is often constrained by the slow trans-cleavage activity of Cas enzymes, necessitating preamplification of target nucleic acids.
View Article and Find Full Text PDFDiagnostic challenges due to hepatitis B virus surface antigen mutations outside the major hydrophilic region.
Arch Virol
March 2025
Infectious Diseases and Immunology Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), 4, Raja S.C. Mullick Road, Kolkata, West Bengal, 700032, India.
The number of observed cases of occult hepatitis B virus infection (OBI) in eastern India has been increasing. Here, S gene mutations were identified in apparently healthy individuals with OBI, and the S protein variants from these patients were characterized in vitro. Plasma samples from 217 healthy blood donors were collected from three different regions in eastern India and screened for hepatitis B virus (HBV) infection using a nucleic acid amplification test and immunoassays for serological markers.
View Article and Find Full Text PDFThis study characterized a hepatitis B virus (HBV) hybridization-capture next-generation sequencing (HBV-NGS) assay and applied it to develop a model for estimating the integrated HBV DNA (iDNA) quantity and for HBV genetics liquid biopsy. Using HBV monomers and reconstituted cell line DNA (SNU398, Hep3B, and PLC/PRF/5), the HBV-NGS assay demonstrated high coverage uniformity, reproducibility across HBV genotypes A-D, and 0.1% sensitivity for detecting iDNA.
View Article and Find Full Text PDFFlavonoids of Andrographis paniculata regulate hepatitis B virus replication and hepatocellular carcinoma progression: evidence from computational and experimental studies.
BMC Complement Med Ther
March 2025
ICMR-National Institute of Traditional Medicine, Nehru Nagar, Belagavi, Karnataka, 590010, India.
Background: The HBx protein of hepatitis B virus (HBV) plays a crucial role in HBV pathogenesis, yet current treatments like HIV reverse transcriptase (RT) inhibitors, which target HBV RT due to similar active sites, have severe side effects, risk of drug resistance, and high costs. The present study investigates the anti-hepatitis B virus (HBV) properties of Andrographis paniculata (AP) and Thespesia populnea (TP) on HBV expressing HepG2.2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!